RNA as a target for developing antivirals

Antiviral Chemistry and Chemotherapy

Volumn 14, Issue 2, 2003, Pages 61-73

  McKnight, Kevin L ^a   Heinz, Beverly A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antiviral; Computer modelling; High throughput screening; RNA

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; APTAMER; DOUBLE STRANDED RNA; RIBOZYME; VIRUS RNA;

ANTIVIRAL ACTIVITY; COMPUTER MODEL; DRUG TARGETING; GENE SILENCING; INTERNAL RIBOSOME ENTRY SITE; MOLECULAR INTERACTION; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN RNA BINDING; REVIEW; RNA STRUCTURE; SCREENING; VIRUS GENOME; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0038802598     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020301400201     Document Type: Review

References (111)

1. Agrawal S & Zhao Q (1998) Antisense therapeutics. Current Opinion in Chemical Biology 2:519-528.
2. Alper PB, Hendrix M, Sears P & Wong C-H (1998) Probing the specificity of aminoglycoside-ribosomal RNA interactions with designed synthetic analogs. Journal of the American Chemical Society 120:1965-1978.
3. Amarasinghe GK, De Guzman RN, Turner RB, Chancellor, KJ, Wu ZR & Summers MF (2000) NMR structure of the HIV-1 nucleocapsid protein bound to stem-loop SL2 of the psi-RNA packaging signal. Implications for genome recognition. Journal of Molecular Biology 301:491-511.
4. Amarasinghe GK, Zhou J, Miskimon M, Chancellor KJ, McDonald JA, Matthews AG, Miller RR, Rouse MD & Summers MF (2001) Stem-loop SL4 of the HIV-1 psi RNA packaging signal exhibits weak affinity for the nucleocapsid protein. structural studies and implications for genome recognition. Journal of Molecular Biology 314:961-970.
5. Amyes SG (1998) Genes and spectrum: the theoretical limits. Clinical Infectious Diseases 27(Suppl. 1):S21-S28.
6. Anderson KP, Fox MC, Brown-Driver V, Martin MJ & Azad RF (1996) Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrobial Agents & Chemotherapy 40:2004-2011.
7. Andino R, Rieckhof GE, Achacoso PL & Baltimore D (1993) Poliovirus RNA synthesis utilizes an RNP complex formed around the 5′-end of viral RNA. EMBO Journal 12:3587-3598.
8. Azad RF, Driver VB, Tanaka K, Crooke RM & Anderson KP (1993) Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrobial Agents & Chemotherapy 37:1945-1954.
9. Bailly C, Colson P, Houssier C & Hamy F (1996) The binding mode of drugs to the TAR RNA of HIV-1 studied by electric linear dichroism. Nucleic Acids Research 24:1460-1464.
10. Baltimore D (1988) Gene therapy. Intracellular immunization. Nature 335:395-396.
11. Barton DJ, Morasco BJ & Flanegan JB (1996) Assays for poliovirus polymerase, 3D(Pol), and authentic RNA replication in HeLa S10 extracts. Methods of Enzymology 275:35-57.
12. Battiste JL, Mao H, Rao NS, Tan R, Muhandiram DR, Kay LE, Frankel AD & Williamson JR (1996) α-Helix-RNA major groove recognition in an HIV-1 rev peptide-RRE RNA complex. Science 273:1547-1551.
13. Branch AD (1998) A good antisense molecule is hard to find. Trends in Biochemical Sciences 23:45-50.
14. Brown-Driver V, Eto T, Lesnik E, Anderson KP & Hanecak RC (1999) Inhibition of translation of hepatitis C virus RNA by 2-modified antisense oligonucleotides. Antisense Nucleic Acid Drug Development 9:145-154.
15. Capodici J, Kariko K & Weissman D (2002) Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. Journal of Immunology 169:5196-5201.
16. Chen Q Shafer RH & Kuntz ID (1997) Structure-based discovery of ligands targeted to the RNA double helix. Biochemistry 36:11402-11407.
17. Cirino NM, Li G, Xiao W, Torrence PF & Silverman RH (1997) Targeting RNA decay with 2′,5′ oligoadenylate-antisense in respiratory syncytial virus-infected cells. Proceedings of the National Academy of Sciences, USA 94:1937-1942.
18. Coburn GA & Cullen BR (2002) Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. Journal of Virology 76:9225-9231.
19. Collier AJ, Gallego J, Klinck R, Cole PT, Harris SJ, Harrison GP, Aboul-Ela F, Varani G & Walker S (2002) A conserved RNA structure within the HCV IRES eIF3-binding site. Nature Structural Biology 9:375-380.
20. Crooke ST (2000) Progress in antisense technology: the end of the beginning. Methods in Enzymology 313:3-45.
21. Darfeuille F, Arzumanov A, Gait MJ, Di Primo C & Toulme JJ (2002a) 2′-O-methyl-RNA hairpins generate loop-loop complexes and selectively inhibit HIV-1 Tat-mediated transcription. Biochemistry 41:12186-12192.
22. Darfeuille F, Arzumanov A, Gryaznov S, Gait MJ, Di Primo C & Toulme JJ (2002b) Loop-loop interaction of HIV-1 TAR RNA with N3′->P5′ deoxyphosphoramidate aptamers inhibits in vitro Tat-mediated transcription. Proceedings of the National Academy of Sciences, USA 99:9709-9714.
23. Dingwall C, Ernberg I, Gait MJ, Green SM, Heaphy S, Karn J, Lowe AD, Singh M & Skinner MA (1990) HIV-1 tat protein stimulates transcription by binding to a U-rich bulge in the stem of the TAR RNA structure. EMBO Journal 9:4145-4153.
24. Domingo E, Ruiz-Jarabo CM, Sierra S, Arias A, Pariente N, Baranowski E & Escarmis C (2002) Emergence and selection of RNA virus variants: memory and extinction. Virus Research 82:39-44.
25. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J & Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine 2:561-566.
26. Du Z, Lind KE & James TL (2002) Structure of TAR RNA complexed with a Tat-TAR interaction nanomolar inhibitor that was identified by computational screening. Chemistry & Biology 9:707-712.
27. Emerman M & Malim MH (1998) HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science 280:1880-1884.
28. Filikov AV, Mohan V, Vickers TA, Griffey RH, Cook PD, Abagyan RA & James T L (2000) Identification of ligands for RNA targets via structure-based virtual screening: HIV-1 TAR. Journal of Computer-Aided Molecular Design 14:593-610.
29. Flodell S, Cromsigt J, Schleucher J, Kidd-Ljunggren K & Wijmenga S (2002) Structure elucidation of the hepatitis B virus encapsidation signal by NMR on selectively labeled RNAs. Journal of Biomolecular Structural & Dynamics 19:627-636.
30. Furukawa H, Momota K, Agatsuma T, Yamamoto I, Kimura S & Shimada K (1997) Identification of a phosphodiester hexanucleotide that inhibits HIV-1 infection in vitro on covalent linkage of its 5′-end with a dimethoxytrityl residue. Antisense Nucleic Acid Drug Development 7:167-175.
31. Gallego J & Varani G (2001) Targeting RNA with small-molecule drugs: therapeutic promise and chemical challenges. Accounts of Chemical Research 34:836-843.
32. Gerber K, Wimmer E & Paul AV (2001) Biochemical and genetic studies of the initiation of human rhinovirus 2 RNA replication: identification of a cis-replicating element in the coding sequence of 2A(pro). Journal of Virology 75:10979-10990.
33. Gitlin L, Karelsky S & Andino R (2002) Short interfering RNA confers intracellular antiviral immunity in human cells. Nature 418:430-434.
34. Giver L, Bartel DP, Zapp ML, Green MR & Ellington AD (1993) Selection and design of high-affinity RNA ligands for HIV-1 Rev. Gene 137:19-24.
35. Gunzburg W, Mhashilkar AM & Hindi M (1999) Technology evaluation: StealthVector (HIV) Enzo. Current Opinion in Molecular Therapy 1:651-657.
36. Hamy F, Felder ER, Heizmann G, Lazdins J, Aboul-ela F, Varani G, Karn J & Klimkait T (1997) An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proceedings of the National Academy of Sciences, USA 94:3548-3553.
37. Hanecak R, Brown-Driver V, Fox MC, Azad RF, Furusako S, Nozaki C, Ford C, Sasmor H & Anderson KP (1996) Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. Journal of Virology 70:5203-5212.
38. Hendrix M, Priestley ES, Joyce GF & Wong CH (1997) Direct observation of aminoglycoside-RNA interactions by surface plasmon resonance. Journal of the American Chemical Society 119:3641-3648.
39. Hermann T & Westhof E (1998) RNA as a drug target: chemical, modelling, and evolutionary tools. Current Opinion in Biotechnology 9:66-73.
40. Hermann T & Westhof E (1999) Docking of cationic antibiotics to negatively charged pockets in RNA folds. Journal of Medicinal Chemistry 42:1250-1261.
41. Hofstadler SA, Sannes-Lowery KA, Crooke ST, Ecker DJ, Sasmor H, Manalili S & Griffey RH (1999) Multiplexed screening of neutral mass-tagged RNA targets against ligand libraries with electrospray ionization FTICR MS: a paradigm for high-throughput affinity screening. Analytical Chemistry 71:3436-3440.
42. Honda M, Beard MR, Ping LH & Lemon SM (1999) A phylogenetically conserved stem-loop structure at the 5′ border of the internal ribosome entry site of hepatitis C virus is required for cap-independent viral translation. Journal of Virology 73:1165-1174.
43. Ippolito JA & Steitz TA (1998) A 1.3-A resolution crystal structure of the HIV-1 trans-activation response region RNA stem reveals a metal ion-dependent bulge conformation. Proceedings of the National Academy of Sciences, USA 95:9819-9824.
44. Ippolito JA & Steitz TA (2000) The structure of the HIV-1 RRE high affinity rev binding site at 1.6 A resolution. Journal of Molecular Biology 295:711-717.
45. Jacque JM, Triques K & Stevenson M (2002) Modulation of HIV-1 replication by RNA interference. Nature 418:435-438.
46. Jubin R, Vantuno NE, Kieft JS, Murray MG, Doudna JA, Lau JY & Baroudy BM (2000) Hepatitis C virus internal ribosome entry site (IRES) stem loop IIId contains a phylogenetically conserved GGG triplet essential for translation and IRES folding. Journal of Virology 74:10430-10437.
47. Kapadia SB, Brideau-Andersen A & Chisara FV (2003). Interference of hepatitis C virus RNA replication by short interfering RNAs. 100:2014-2018.
48. Kieft JS, Zhou K, Grech A, Jubin R & Doudna JA (2002) Crystal structure of an RNA tertiary domain essential to HCV IRES-mediated translation initiation. Nature Structural Biology 9:370-374.
49. Kim I, Lukavsky PJ & Puglisi JD (2002) NMR study of 100 kDa HCV IRES RNA using segmental isotope labeling. Journal of the American Chemical Society 124:9338-9339.
50. Klinck R, Westhof E, Walker S, Afshar M, Collier A & Aboul-Ela F (2000) A potential RNA drug target in the hepatitis C virus internal ribosomal entry site. RNA 6:1423-1431.
51. Leaman DW, Longano FJ, Okicki JR, Soike KF, Torrence PF, Silverman RH & Cramer H (2002) Targeted therapy of respiratory syncytial virus in African green monkeys by intranasally administered 2-5A antisense. Virology 292:70-77.
52. Leclerc F & Cedergren R (1998) Modeling RNA-ligand interactions: the Rev-binding element RNA-aminoglycoside complex. Journal of Medicinal Chemistry 41:175-182.
53. Lee PA, Blatt LM, Blanchard KS, Bouhana KS, Pavco PA, Bellon L & Sandberg JA (2000) Pharmacokinetics and tissue distribution of a ribozyme directed against hepatitis C virus RNA following subcutaneous or intravenous administration in mice. Hepatology 32:640-646.
54. Lewis EJ, Agrawal S, Bishop J, Chadwick J, Cristensen ND, Cuthill S, Dunford P, Field AK, Francis J, Gibson V, Greenham AK, Kelly F, Kilkushie R, Kreider JW, Mills JS, Mulqueen M, Roberts NA, Roberts P & Szymkowski DE (2000) Non-specific antiviral activity of antisense molecules targeted to the E1 region of human papillomavirus. Antiviral Research 48:187-196.
55. Lim AC & Barton JK (1997) Targeting the Tat-binding site of bovine immunodeficiency virus TAR RNA with a shape-selective rhodium complex. Bioorganic & Medicinal Chemistry 5:1131-1136.
56. Lima WF, Brown-Driver V, Fox M, Hanecak R & Bruice TW (1997) Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity. Journal of Biological Chemistry 272:626-638.
57. Lind KE, Du Z, Fujinaga K, Peterlin BM & James TL (2002) Structure-based computational database screening, in vitro assay, and NMR assessment of compounds that target TAR RNA. Chemistry & Biology 9:185-193.
58. Litovchick A, Lapidot A, Eisenstein M, Kalinkovich A & Borkow G (2001) Neomycin B-arginine conjugate, a novel HIV-1 Tat antagonist: synthesis and anti-HIV activities. Biochemistry 40:15612-15625.
59. Lorsch JR & Szostak JW (1994) In vitro selection of RNA aptamers specific for cyanocobalamin. Biochemistry 33:973-982.
60. Lott WB, Takyar SS, Tuppen J, Crawford DH, Harrison M, Sloots TP & Gowans EJ (2001) Vitamin B12 and hepatitis C: molecular biology and human pathology. Proceedings of the National Academy of Sciences, USA 98:4916-4921.
61. Lukavsky PJ, Otto GA, Lancaster AM, Sarnow P & Puglisi JD (2000) Structures of two RNA domains essential for hepatitis C virus internal ribosome entry site function. Nature Structural Biology 7:1105-1110.
62. Lukavsky PJ & Puglisi JD (2001) RNAPack: an integrated NMR approach to RNA structure determination. Methods 25:316-332.
63. Macejak DG, Jensen KL, Pavco PA, Phipps KM, Heinz BA, Colacino JM & Blatt LM (2001) Enhanced antiviral effect in cell culture of type 1 interferon and ribozymes targeting HCV RNA. Journal of Viral Hepatitis 8:400-405.
64. Mann DA, Mikaelian I, Zemmel RW, Green SM, Lowe AD, Kimura T, Singh M, Butler PJ, Gait MJ & Karn J (1994) A molecular rheostat. Co-operative rev binding to stem I of the rev-response element modulates human immunodeficiency virus type-1 late gene expression. Journal of Molecular Biology 241:193-207.
65. Marozzi A, Meneveri R, Giacca M, Gutierrez MI, Siccardi AG & Ginelli E (1998) In vitro selection of HIV-1 TAR variants by the Tat protein. Journal of Biotechnology 61:117-128.
66. Martinez MA, Gutierrez A, Armand-Ugon M, Blanco J, Parera M, Gomez J, Clotet B & Este JA (2002) Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS 16:2385-2390.
67. McKnight KL & Lemon SM (1998) The rhinovirus type 14 genome contains an internally located RNA structure that is required for viral replication. RNA 4:1569-1584.
68. McPike MP, Sullivan JM, Goodisman J & Dabrowiak JC (2002) Footprinting, circular dichroism and UV melting studies on neomycin B binding to the packaging region of human immunodeficiency virus type-1 RNA. Nucleic Acids Research 30:2825-2831.
69. Mei HY, Mack DP, Galan AA, Halim NS, Heldsinger A, Loo JA, Moreland DW, Sannes-Lowery KA, Sharmeen L, Truong HN & Czarnik AW (1997) Discovery of selective, small-molecule inhibitors of RNA complexes-I. The Tat protein/TAR RNA complexes required for HIV-1 transcription. Bioorganic & Medicinal Chemistry 5:1173-1184.
70. Muesing MA, Smith DH & Capon DJ (1987) Regulation of mRNA accumulation by a human immunodeficiency virus trans-activator protein. Cell 48:691-701.
71. Nifosi R, Reyes CM & Kollman PA (2000) Molecular dynamics studies of the HIV-1 TAR and its complex with argininamide. Nucleic Acids Research 28:4944-4955.
72. Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee SK, Collman RG, Lieberman J, Shankar P & Sharp PA (2002) siRNA-directed inhibition of HIV-1 infection. Nature Medicine 8:681-686.
73. Opalinska JB & Gewirtz AM (2002) Nucleic-acid therapeutics: basic principles and recent applications. Nature Reviews Drug Discovery 1:503-514.
74. Orr RM (2001) Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision. Current Opinion in Molecular Therapy 3:288-294.
75. Park WKC, Auer M, Jaksche H & Wong C-H (1996) Rapid combinatorial synthesis of aminoglycoside antibiotic mimetics: use of a polyethylene glycol-linked amine and a neamine-derived aldehyde in multiple component condensation as a strategy for the discovery of new inhibitors of the HIV RNA rev responsive element. Journal of the American Chemical Society 118:10150-10155.
76. Paul AV, Rieder E, Kim DW, van Boom JH & Wimmer E (2000) Identification of an RNA hairpin in poliovirus RNA that serves as the primary template in the in vitro uridylylation of VPg. Journal of Virology 74:10359-10370.
77. Peterson RD & Feigon J (1996) Structural change in Rev responsive element RNA of HIV-1 on binding Rev peptide. Journal of Molecular Biology 264:863-877.
78. Player MR, Maitra RK, Silverman RH & Torrence PF (1998) Targeting RNase L to human immunodeficiency virus RNA with 2-5A-antisense. Antiviral Chemistry & Chemotherapy 9:225-231.
79. Pogue GP, Huntley CC & Hall TC (1994) Common replication strategies emerging from the study of diverse groups of positive-strand RNA viruses. Archives of Virology Supplement 9:181-194.
80. Randall G, Grakoui A & Rice CM (2003) Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proceedings of the National Academy of Sciences, USA 100:235-240.
81. Ratmeyer L, Zapp ML, Green MR, Vinayak R, Kumar A, Boykin DW & Wilson WD (1996) Inhibition of HIV-1 Rev-RRE interaction by diphenylfuran derivatives. Biochemistry 35:13689-13696.
82. Rijnbrand RC & Lemon SM (2000) Internal ribosome entry site-mediated translation in hepatitis C virus replication. Current Topics in Microbiology & Immunology 242:85-116.
83. Rogers J, Chang AH, von Ahsen U, Schroeder R & Davies J (1996) Inhibition of the self-cleavage reaction of the human hepatitis delta virus ribozyme by antibiotics. Journal of Molecuar Biology 259:916-925.
84. Sannes-Lowery KA, Griffey RH & Hofstadler SA (2000) Measuring dissociation constants of RNA and aminoglycoside antibiotics by electrospray ionization mass spectrometry. Analytical Biochemistry 280:264-271.
85. Sannes-Lowery KA, Hu P, Mack DP, Mei HY & Loo JA (1997) HIV-1 Tat peptide binding to TAR RNA by electrospray ionization mass spectrometry. Analytical Chemistry 69:5130-5135.
86. Seo MY, Abrignani S, Houghton M & Han JH (2003) Small Interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7. Journal of Virology 77:810-812.
87. Sharp PA (2001) RNA interference-2001. Genes & Development 15:485-490.
88. Silverman RH, Dong B, Maitra RK, Player MR & Torrence PF (2000) Selective RNA cleavage by isolated RNase L activated with 2-5A antisense chimeric oligonucleotides. Methods in Enzymology 313:522-533.
89. Smith DB, Pathirana S, Davidson F, Lawlor E, Power J, Yap PL & Simmonds P (1997) The origin of hepatitis C virus genotypes. Journal of General Virology 78:321-328.
90. Swayze EE, Jefferson EA, Sannes-Lowery KA, Blyn LB, Risen LM, Arakawa S, Osgood SA, Hofstadler SA & Griffey RH (2002) SAR by MS: a ligand based technique for drug lead discovery against structured RNA targets. Journal of Medicinal Chemistry 45:3816-3819.
91. Takyar SS, Gowans EJ & Lott WB (2002) Vitamin B12 stalls the 80 s ribosomal complex on the hepatitis C internal ribosome entry site. Journal of Molecular Biology 319:1-8.
92. Tan R, Brodsky A, Williamson JR & Frankel AD (1997) RNA recognition by HIV-1 Tat and Rev. Seminars in Virology 8:186-193.
93. Urvil PT, Kakiuchi N, Zhou DM, Shimotohno K, Kumar PK & Nishikawa S (1997) Selection of RNA aptamers that bind specifically to the NS3 protease of hepatitis C virus. European Journal of Biochemistry 248:130-138.
94. Usman N, Beigelman L & McSwiggen JA (1996) Hammerhead ribozyme engineering. Current Opinion in Structural Biology 6:527-533.
95. Usman N & Blatt LM (2000) Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. Journal of Clinical Investigation 106:1197-1202.
96. Wang S, Huber PW, Cui M, Czarnik AW & Mei HY (1998) Binding of neomycin to the TAR element of HIV-1 RNA induces dissociation of Tat protein by an allosteric mechanism. Biochemistry 37:5549-5557.
97. Wang W, Preville P, Morin N, Mounir S, Cai W & Siddiqui MA (2000) Hepatitis C viral IRES inhibition by phenazine and phenazine-like molecules. Bioorganic & Medicinal Chemistry Letters 10:1151-1154.
98. Wang Y, Hamasaki K & Rando RR (1997) Specificity of aminoglycoside binding to RNA constructs derived from the 16S rRNA decoding region and the HIV-RRE activator region. Biochemistry 36:768-779.
99. Wilson WD & Li K (2000) Targeting RNA with small molecules. Current Medicinal Chemistry 7:73-98.
100. Wilson WD, Ratmeyer L, Zhao M, Ding D, McConnaughie AW, Kumar A & Boykin DW (1996) Design and analysis of RNA structure-specific agents as potential antivirals. Journal of Molecular Recognition 9:187-196.
101. Witherell GW (2001) ISIS-14803 (Isis Pharmaceuticals). Current Opinion in Investigational Drugs 2:1523-1529.
102. Wong C-H, Hendrix M, Manning DD, Rosenbohm C & Greenberg WA (1998) A library approach to the discovery of small molecules that recognize RNA: use of a 1,3-hydroxyamine motif as core. Journal of the American Chemical Society 120:8319-8327.
103. Xiao G, Kumar A, Li K, Rigl CT, Bajic M, Davis TM, Boykin DW & Wilson WD (2001) Inhibition of the HIV-1 rev-RRE complex formation by unfused aromatic cations. Bioorganic & Medicinal Chemistry 9:1097-1113.
104. Yang Y, Rijnbrand R, McKnight KL, Wimmer E, Paul A, Martin A & Lemon SM (2002) Sequence requirements for viral RNA replication and VPg uridylylation directed by the internal cis-acting replication element (cre) of human rhinovirus type 14. Journal of Virology 76:7485-7494.
105. Yao S & Wilson WD (1992) A molecular mechanics investigation of RNA complexes. I. Ethidium intercalation in an HIV-1 TAR RNA sequence with an unpaired adenosine. Journal of Biomolecular Structural Dynamics 10:367-387.
106. Yuen AR, Halsey J, Fisher GA, Holmlund JT, Geary RS, Kwoh TJ, Dorr A & Sikic BI (1999) Phase I study of an antisense oligonucleotide to protein kinase C-α (ISIS 3521/CGP 64128A) in patients with cancer. Clinical Cancer Research 5:3357-3363.
107. Zapp ML, Young DW, Kumar A, Singh R, Boykin DW, Wilson WD & Green MR (1997) Modulation of the Rev-RRE interaction by aromatic heterocyclic compounds. Bioorganic & Medicinal Chemistry 5:1149-1155.
108. Zeffman A, Hassard S, Varani G & Lever A (2000) The major HIV-1 packaging signal is an extended bulged stem loop whose structure is altered on interaction with the Gag polyprotein. Journal of Molecular Biology 297:877-893.
109. Zhang H, Hanecak R, Brown-Driver V, Azad R, Conklin B, Fox MC & Anderson KP (1999) Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant. Antimicrobial Agents & Chemotherapy 43:347-353.
110. Zhao WD & Wimmer E (2001) Genetic analysis of a poliovirus/hepatitis C virus chimera: new structure for domain II of the internal ribosomal entry site of hepatitis C virus. Journal of Virology 75:3719-3730.
111. Zheng R (1999) Technology evaluation: GEM-92, Hybridon Inc. Current Opinion in Molecular Therapy 1:521-523.